Skip to content

Comparison of Rotational stability of Toric IOL

Assessment of Toric IOL Rotational stability between three Toric IOLs - nil

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/089880
Enrollment
150
Registered
2025-06-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H259- Unspecified age-related cataract

Interventions

Intervention1: To analyse and compare the rotational stability of three toric IOL S- Eyecryl toric (Biotech), Clareon toric (Alcon) , Eyehance toric (Johnson & Johnson).: to assess the rotational sta

Sponsors

Nethradhama superspeciality eye hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Unilateral implant; Eyes with grade 1-4 nuclear sclerosis, cortical cataracts, posterior subcapsular cataract Eyes with regular corneal astigmatism 0.75-5D In the bag IOL implantation

Exclusion criteria

Exclusion criteria: Corneal disorders like- irregular astigmatism, keratoconus, pellucid marginal degeneration, corneal dystrophy, low endothelial cell counts Post refractive surgery, History of any previous ocular surgery Complicated cataract Glaucoma, posterior segment pathology retinopathy History of uveitis.

Design outcomes

Primary

MeasureTime frame
1.To analyse and compare the rotational stability of three toric IOL S- Eyecryl toric (Biotech), Clareon toric (Alcon) , Eyehance toric (Johnson & Johnson).Timepoint: performed for 1 day, 2 weeks, and 3 months after surgery.

Secondary

MeasureTime frame
2. To assess visual acuity between three toric IOLs - Eyecryl toric (Biotech), Clareon toric (Alcon) , Eyehance toric (Johnson & Johnson).Timepoint: performed for 1 day, 2 weeks, and 3 months after surgery.

Countries

India

Contacts

Public ContactDr Bala Harshita

Nethradhama superspeciality eye hospital

sush.samak@gmail.com9448071800

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026